Dr. Hugh Hetherington Publishes New Study in Clinical, Cosmetic and Investigational Dermatology Journal
San Francisco, CA, October 22, 2013 --(PR.com)-- Injection Technologies, a dynamic early-stage medical device company developing a revolutionary method for automating fluid delivery, is pleased to announce the recent publication of Facial Fat Grafting With a Prototype Injection Control Device in the journal Clinical, Cosmetic and Investigational Dermatology. Co-authored by Dr. Hugh Hetherington and Dr. Jon Block of Injection Technologies, the purpose of this study was to evaluate the initial clinical performance of a prototype injection control device (ICD) to facilitate fat grafting by injection.
The results of the study confirmed that the desired degree of correction was more consistent, recovery was faster, and procedural efficiency was improved when performing the procedure with the ICD compared to historical use of the manual method of injection. The ICD optimally distributes fat as a uniform thread along the withdrawal tract of the cannula, thereby eliminating clumping and minimizing tissue trauma, resulting in reduced recovery time as well as more consistent and predictable clinical results. Since the ICD automates the injection process, it provides a notable and easily attainable efficiency in procedural time and minimal learning curve for the user.
“Publication of this inaugural article represents an important milestone in the ongoing development of the ICD,” commented company CEO Jon E. Block, Ph.D. “We place great value on the importance and global reach that peer reviewed publications provide and remain committed to rapid commercialization of the ICD for a broad array of clinical indications.”
About Injection Technologies
Injection Technologies is an exciting, dynamic early-stage medical device company sharply focused on commercializing a unique technology platform that utilizes a revolutionary method for automating the delivery of synthetic, autologous, allogeneic and bioactive fluids, gels, and matrices in pre-specified volume quantities. Using a patented injection control device, our overarching goal is to provide the physician with a hand-held instrument that distributes a reproducible amount of material within soft and osseous tissues. The Company is aggressively pursuing the controlled delivery of synthetic dermal fillers such as hyaluronic acid analogs for cosmetic facial rejuvenation as an initial indication for use. In this setting, the device allows for the dermal injection of uniform “threads” of material allowing for consistent aesthetic results. In short, it replaces the standard syringe for injecting facial fillers. For more information, please visit www.injection-technologies.com.
The results of the study confirmed that the desired degree of correction was more consistent, recovery was faster, and procedural efficiency was improved when performing the procedure with the ICD compared to historical use of the manual method of injection. The ICD optimally distributes fat as a uniform thread along the withdrawal tract of the cannula, thereby eliminating clumping and minimizing tissue trauma, resulting in reduced recovery time as well as more consistent and predictable clinical results. Since the ICD automates the injection process, it provides a notable and easily attainable efficiency in procedural time and minimal learning curve for the user.
“Publication of this inaugural article represents an important milestone in the ongoing development of the ICD,” commented company CEO Jon E. Block, Ph.D. “We place great value on the importance and global reach that peer reviewed publications provide and remain committed to rapid commercialization of the ICD for a broad array of clinical indications.”
About Injection Technologies
Injection Technologies is an exciting, dynamic early-stage medical device company sharply focused on commercializing a unique technology platform that utilizes a revolutionary method for automating the delivery of synthetic, autologous, allogeneic and bioactive fluids, gels, and matrices in pre-specified volume quantities. Using a patented injection control device, our overarching goal is to provide the physician with a hand-held instrument that distributes a reproducible amount of material within soft and osseous tissues. The Company is aggressively pursuing the controlled delivery of synthetic dermal fillers such as hyaluronic acid analogs for cosmetic facial rejuvenation as an initial indication for use. In this setting, the device allows for the dermal injection of uniform “threads” of material allowing for consistent aesthetic results. In short, it replaces the standard syringe for injecting facial fillers. For more information, please visit www.injection-technologies.com.
Contact
Jon Block Group
Kurt Burgess
(415) 601-9436
www.jonblockgroup.com
Kurt Burgess
(415) 601-9436
www.jonblockgroup.com
Contact
Categories